{"nctId":"NCT04581395","briefTitle":"The Effect of Pretreatment With Roc on Succinylcholine Myalgias","startDateStruct":{"date":"2020-10-02","type":"ACTUAL"},"conditions":["Myalgia"],"count":300,"armGroups":[{"label":"Not pretreated","type":"OTHER","interventionNames":["Other: non-pretreated Succinylcholine"]},{"label":"Pre-treated 1 minute before succinylcholine administration","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: succinylcholine 1 minute after rocuronium pretreatment"]},{"label":"Pre-treated 2 minutes before succinylcholine administratjion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: succinylcholine 2 minutes following rocuronium pretreatment"]}],"interventions":[{"name":"non-pretreated Succinylcholine","otherNames":["Control group"]},{"name":"succinylcholine 1 minute after rocuronium pretreatment","otherNames":["rocuronium pretreatment 1 minute before succinylcholine administration"]},{"name":"succinylcholine 2 minutes following rocuronium pretreatment","otherNames":["rocuronium pretreatment 2 minutes before succinylcholine administration"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Undergoing elective Endoscopic Retrograde Cholangiopancreatography (ERCP) under general anesthesia\n* Have been informed of the nature of the study and informed consent has been obtained\n\nExclusion Criteria:\n\n* Patients will be excluded if they have chronic pain requiring daily opioid use greater than 30 mg PO morphine equivalent.\n* Patients will also be excluded if their comorbid medical conditions require a true rapid sequence induction as precurarization with rocuronium increases the time to intubation which is undesirable in a patient who is at high risk for aspiration.\n* Patients taking muscle relaxants at home for spasticity.\n* Patients under the age of 18 years old.\n* Any contraindication for using succinylcholine or rocuronium.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Myalgias Perceived at 3 Hours","description":"The data are reported as pain (scores 1-4) vs. no pain (score 0).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"83","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Myalgias at 24 Hours Post Succinylcholine Administration.","description":"The presence of myalgias referencing a severity scale from 0 (no muscle pain), 1 (mild muscle pain), 2(moderate muscle pain), 3 (Moderate muscle pain) and 4 (Severe muscle pain). The data are reported as pain (scores 1-4) vs. no pain (score 0)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"80","spread":null}]},{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"Pain Scores","description":"0=no muscle pain/stiffness, 1=mild muscle pain/stiffness not limiting daily activity, 2=moderate muscle pain/stiffness not limiting daily activity, 3=moderate muscle pain stiffness that limits daily activity, 4=severe muscle pain/stiffness limiting movement and preventing daily activity. Values averaged.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Pain Scores","description":"0=no muscle pain/stiffness, 1=mild muscle pain/stiffness not limiting daily activity, 2=moderate muscle pain/stiffness not limiting daily activity, 3=moderate muscle pain stiffness that limits daily activity, 4=severe muscle pain/stiffness limiting movement and preventing daily activity. Values averaged.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"78","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Observed Presence of Muscle Fasciculation Following Succinylcholine Administration","description":"Observed presence or absence of muscle fasciculation following succinylcholine administration in subjects pretreated with rocuronium 1 minute prior to succinylcholine administration or 2 minutes prior to succinylcholine administration compared to the control group not pretreated with rocuronium.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":[]}}}